The global CRISPR/Cas9
licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier & Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Contact us

"This is transformative technology that allows the recoding of life and editing"

Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 85 issued patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.
Learn more

Latest news

A Year Since BIO
Posted on
One Year On: The Future of CRISPR is Now  As I prepare for my second BIO-International Convention as CEO of ...
CVC successfully appeals prior CRISPR U.S. patent decision
Posted on
U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute ...
AI + CRISPR: Powering the 21st Century’s Biological Revolution 
Posted on
We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power ...
Licensee Case Study: Bioneer
Posted on
Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the ...
ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement 
Posted on
License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities    Dublin, Ireland, and ...
European Patent Office Grants CVC Portfolio Key CRISPR Patent
Posted on
European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and ...
Annual Letter From The CEO
Posted on
Dear Stakeholders, As we step into 2025, I’d like to take a moment to reflect on the remarkable progress we’ve ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9 
Posted on
  The new Express License service removes barriers to accessing this transformative gene editing technology for startups.  An Express License ...
A Letter from the CEO
Posted on
  ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial ...
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement
Posted on
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene ...